Table 1.
Demographic and clinical characteristics and PAM 50 intrinsic subtypes by HIV status
| Overall (n = 377) | HIV-positive* (n = 176) | HIV-negative* (n = 200) | p-value | |
|---|---|---|---|---|
| Age at diagnosis (years) | 48 (42–57) | 46 (41–53) | 51 (44–59) | < 0.001 |
| Stage at diagnosis† | p = 0.404 | |||
| Stage 1 | 13 (3.5%) | 7 (4.0%) | 6 (3.0%) | p = 0.605 |
| Stage 2 | 151 (40.1%) | 65 (36.9%) | 86 (43.0%) | p = 0.231 |
| Stage 3 | 171 (45.4%) | 80 (45.5%) | 90 (45.0%) | p = 0.930 |
| Stage 4 | 42 (11.1%) | 24 (13.6%) | 18 (9.0%) | p = 0.154 |
| Early Stage (1 and 2) | 164 (43.5%) | 72 (40.9%) | 92 (46.0%) | p = 0.321 |
| Advanced Stage (3 and 4) | 213 (56.5%) | 104 (59.1%) | 108 (54.0%) | |
| Molecular Subtype | p = 0.115 | |||
| Luminal A | 73 (19.4%) | 39 (22.2%) | 34 (17.0%) | p = 0.207 |
| Luminal B | 122 (32.1%) | 47 (26.7%) | 75 (37.5%) | p = 0.026 |
| HER2-enriched | 89 (23.9%) | 41 (23.3%) | 47 (23.5%) | p = 0.963 |
| Basal-like | 93 (24.7%) | 49 (27.8%) | 44 (22.0%) | p = 0.190 |
| Risk of recurrence | p = 0.677 | |||
| Low | 33 (8.8%) | 14 (8.0%) | 19 (9.85%) | p = 0.597 |
| Intermediate | 36 (9.6%) | 15 (8.5%) | 21 (10.5%) | p = 0.516 |
| High | 308 (81.7%) | 147 (83.5%) | 160 (80.0%) | p = 0.379 |
| ROR score (median (IQR)) | 67 (55–80) | 65.5 (53–79) | 68 (56–82) | p = 0.222 |
| Lost to Follow-up | 55 (14.6%) | 21 (11.9%) | 33 (16.6%) | p = 0.200 |
| For HIV-positive patients | ||||
| Detectable viral load | 66 (43.1%) | |||
| Viral load, copies/ml (median (IQR)) | 2195 (215–59,096) | |||
| CD4 count, cells/mm3 (median (IQR)) | 450.5 (271–677.5) | |||
| Duration of HIV sero-positivity | ||||
| ≤ 1 year | 66 (38.2%) | |||
| > 1 year | 107 (61.9%) | |||
| On ART | 124 (71.3%) | |||
| Duration of ART use | ||||
| ≤ 1 year | 20 (17.0%) | |||
| > 1 year | 98 (83.1%) |
*1 (0.3%) patients had an unknown HIV status
†Staging was performed clinically during the initial diagnostic exam